(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 21 April 2005 (21.04.2005)

(10) International Publication Number WO 2005/035779 A3

(51) International Patent Classification7: 39/00

A61K 31/70,

(21) International Application Number:

PCT/US2004/033391

(22) International Filing Date: 12 October 2004 (12.10.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/510,086 10 October 2003 (10.10.2003) US 60/526,571 4 December 2003 (04.12.2003) US 60/567,771 5 May 2004 (05.05.2004) US

- (71) Applicant (for all designated States except US): POW-DERJECT VACCINES, INC [US/US]; 585 Science Drive, Madison, WI 53711 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Option, Maisson, WI 53711 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRAUN, Ralph, Patrick (US/US): 8551 Research Way Blvd., Middleton, US 53562 (US).

(74) Agent: PEET, Richard, C.; FOLEY & LARDNER, 3000 K Street, N.W., Suite 500, Washington, DC 20007-5143 (US).

(75) Abstract: The invention relates to a method of eliciting a T cell response against a T cell epitope in a host mammalian subject, which method comprises: (i) a first immunisation that comprises at least two administrations which are from 1 to 14 days apart to the subject, wherein each administration comprises administration of the first immunisation, optionally (ii) a second immunisation that comprises at least one administration to the subject of (a) a NOI encoding the T cell epitope, or (b) a protein comprising the T cell epitope, wherein the time between the first administration of the first immunisation, and the first administration of the second immunisation, is from 21 to 365 days.

